Liquid Biopsies – Products

Distinguish 5mC & 5hmC together with all 4 canonical bases to measure multiple modes of biology from a 5ng cfDNA sample in a single experiment. Identify new multimodal biomarkers to gain transformative insight into current & future states of disease.

Collaboration aims to provide researchers cutting-edge tools to enable transformational monitoring of key biomarkers in solid tissue transplants.

Collaboration aims to grow clinical evidence supporting the use of bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.

Highly sensitive and multiplexed assay for the detection, discrimination, and quantification of key mutations in ESR1 gene for breast cancer, developed for bio-Rad’s QX600™ droplet digital™ PCR system.

Antibodies validated for use with bio-Rad’s Celselect slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance. Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications

Tecan is announcing a streamlined solution portfolio to enable liquid biopsy applications, from upstream workflows to downstream analysis for genomics and proteomics applications.

This compendium provides researchers with a portfolio of electrophoresis instruments to support quality control and automation for a more reliable NGS workflow.

The project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial. The Assay will be available as a service in the Babraham Institute’s Flow Cytometry Facility.

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.